Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1
Recruiting
- Conditions
- RAS MutationLung CancerGlioblastomaPancreatic CancerAdvanced Malignant Solid NeoplasmColon Cancer
- Interventions
- Drug: RSC-1255 Dose EscalationDrug: RSC-1255 Dose Expansion
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- RasCal Therapeutics, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT04678648
- Locations
- 🇺🇸
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
🇺🇸Sarah Cannon, SCRI Oncology Partners - Health One, Denver, Colorado, United States
🇺🇸Sarah Cannon, SCRI Oncology Partners, Nashville, Tennessee, United States
News
No news found